FindTrial
Sign In

n-dodecyl-B-D-maltoside

OTHER5 trials

Sponsors

CG Oncology, Inc., Lepu Biopharma Co., Ltd.

Conditions

Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder CancerNon Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder CancerUrologic CancerUrothelial Carcinoma

Phase 2

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
CompletedNCT04387461
CG Oncology, Inc.Non Muscle Invasive Bladder Cancer
Start: 2020-12-08End: 2024-05-28Updated: 2024-09-25
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
RecruitingNCT07283835
Lepu Biopharma Co., Ltd.High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive Bladder Cancer
Start: 2025-12-04End: 2028-12-31Target: 16Updated: 2026-04-23

Phase 3

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Active, not recruitingNCT04452591
CG Oncology, Inc.High-grade Ta/ T1 Papillary Disease Bladder Cancer, Non Muscle Invasive Bladder Cancer
Start: 2020-10-27End: 2031-12-24Target: 190Updated: 2026-07-10
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Active, not recruitingNCT06111235
CG Oncology, Inc.Bladder Cancer, Non Muscle Invasive Bladder Cancer, Urologic Cancer +1
Start: 2023-12-14End: 2029-02-01Updated: 2026-07-01

Unknown Phase

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
NCT06443944
CG Oncology, Inc.Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Urologic Cancer +1
Updated: 2026-09-11

Related Papers

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
2026-08-01
Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
Journal of Clinical Oncology2025-02-101 citations
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
2024-06-0634 citations
Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
Journal of Clinical Oncology2024-06-0110 citations
666 Phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
Regular and Young Investigator Award Abstracts2022-11-013 citations
Abstract CT233: A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Cancer Research2022-06-15
CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).
Journal of Clinical Oncology2022-06-0131 citations
A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Journal of Clinical Oncology2022-02-1620 citations
955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
2021-11-018 citations
426 A phase 3, single-arm study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)
Regular and Young Investigator Award Abstracts2021-11-012 citations